Though the biotech has been dominating this area for a long time, business is still good. In the first quarter, Vertex Pharmaceuticals' revenue increased by 8% year over year to $2.99 billion. The ...

This biotech has a powerful growth story, but one competitive threat could reshape the entire investment case before the ...

Vertex Pharmaceuticals is buying an endocrine treatment specialist for $10 billion.

Biotech stocks are considered extremely high-risk, high-reward investments. Many biotech companies are developing one or more ...

It has been a banner year for biotech buyouts, and these are two of the prime targets.

Biotech is the story at midday Friday, and it’s not a pretty one for shareholders who chased the sector’s monster 2026 run.

That is a big risk investors take when trying to find the winners and losers within the biotech sector. While we made the ...

Shares of Profusa (PFSA) hit a record low on Thursday, crashing 28% after the biotech company announced its second reverse ...

In 2025, biotechnology stocks had their best year since the COVID-19 pandemic, with the market sector’s two major indexes — the SDPR S&P Biotech ETX (NYSE: XBI) and iShares Biotech ETF (NYSE: IBB) — ...

Michael Yee, UBS biotech analyst, joins 'The Exchange' to discuss Yee's thoughts on biotech stocks, what's driving the ...

Biotech investors are finally getting something they haven't seen in years: a friendlier macro environment. Interest rates appear to be stabilizing, FDA activity is picking up again, and large ...